IL278666B2 - Blood biomarkers of stroke - Google Patents

Blood biomarkers of stroke

Info

Publication number
IL278666B2
IL278666B2 IL278666A IL27866620A IL278666B2 IL 278666 B2 IL278666 B2 IL 278666B2 IL 278666 A IL278666 A IL 278666A IL 27866620 A IL27866620 A IL 27866620A IL 278666 B2 IL278666 B2 IL 278666B2
Authority
IL
Israel
Prior art keywords
expression levels
signature
stroke
subject
biomarkers
Prior art date
Application number
IL278666A
Other languages
English (en)
Hebrew (he)
Other versions
IL278666B1 (en
IL278666A (en
Inventor
Serge Timsit
Emmanuelle Genin
Original Assignee
Centre Hospitalier Regional Et Univ De Brest
Francais Du Sang Ets
Inst Nat Sante Rech Med
Univ Bretagne Occidentale
Serge Timsit
Emmanuelle Genin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Regional Et Univ De Brest, Francais Du Sang Ets, Inst Nat Sante Rech Med, Univ Bretagne Occidentale, Serge Timsit, Emmanuelle Genin filed Critical Centre Hospitalier Regional Et Univ De Brest
Publication of IL278666A publication Critical patent/IL278666A/en
Publication of IL278666B1 publication Critical patent/IL278666B1/en
Publication of IL278666B2 publication Critical patent/IL278666B2/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL278666A 2018-05-16 2019-05-16 Blood biomarkers of stroke IL278666B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305600 2018-05-16
PCT/EP2019/062653 WO2019219831A1 (en) 2018-05-16 2019-05-16 Blood biomarkers of stroke

Publications (3)

Publication Number Publication Date
IL278666A IL278666A (en) 2020-12-31
IL278666B1 IL278666B1 (en) 2025-02-01
IL278666B2 true IL278666B2 (en) 2025-06-01

Family

ID=62386311

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278666A IL278666B2 (en) 2018-05-16 2019-05-16 Blood biomarkers of stroke

Country Status (13)

Country Link
US (1) US12247257B2 (https=)
EP (1) EP3794355A1 (https=)
JP (2) JP7463351B2 (https=)
KR (1) KR20210049026A (https=)
CN (1) CN112424609A (https=)
AU (1) AU2019270404B2 (https=)
BR (1) BR112020023259A2 (https=)
CA (1) CA3100171A1 (https=)
IL (1) IL278666B2 (https=)
MA (1) MA52617A (https=)
MX (1) MX2020012297A (https=)
SG (1) SG11202011369VA (https=)
WO (1) WO2019219831A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220093267A1 (en) * 2019-01-22 2022-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Noninvasive real-time patient-specific assessment of stroke severity
CN114107487B (zh) * 2021-12-23 2024-01-09 太原市精神病医院 一种可用于诊断脑卒中的产品
JP2023111774A (ja) * 2022-01-31 2023-08-10 国立研究開発法人国立循環器病研究センター 再灌流療法の適用を決定するバイオマーカー
CN116705296B (zh) * 2023-06-06 2024-09-13 中国科学院深圳先进技术研究院 一种基于常规mri序列对gbm患者进行风险分层的方法及系统
WO2025151599A1 (en) * 2024-01-09 2025-07-17 Morehouse School Of Medicine Rna-based method for stroke assessment and treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104393A1 (en) * 2000-11-28 2003-06-05 Sharp Frank R. Blood assessment of injury
WO2015054700A2 (en) * 2013-10-13 2015-04-16 The Research Foundation For Suny Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof
WO2018067571A2 (en) * 2016-10-03 2018-04-12 West Virginia University Computer implemented discovery of biomarkers for blood brain barrier disruption

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US9005891B2 (en) 2009-11-10 2015-04-14 Genomic Health, Inc. Methods for depleting RNA from nucleic acid samples
US9410204B2 (en) 2012-01-07 2016-08-09 The Regents Of The University Of California Biomarkers for diagnosing ischemia
US20150274815A1 (en) * 2012-09-25 2015-10-01 The United States of America, as represented by the Secretary, Department of Health & Human Servic Treatment of central nervous system (cns) injury
JP2016507235A (ja) * 2013-02-01 2016-03-10 ウエストバージニア ユニバーシティWest Virginia University 脳卒中症状の発症の時点を決定するためのバイオマーカーアルゴリズムおよび方法
CN108291330A (zh) * 2015-07-10 2018-07-17 西弗吉尼亚大学 卒中和卒中严重性的标志物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104393A1 (en) * 2000-11-28 2003-06-05 Sharp Frank R. Blood assessment of injury
WO2015054700A2 (en) * 2013-10-13 2015-04-16 The Research Foundation For Suny Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof
WO2018067571A2 (en) * 2016-10-03 2018-04-12 West Virginia University Computer implemented discovery of biomarkers for blood brain barrier disruption

Also Published As

Publication number Publication date
MA52617A (fr) 2021-03-24
KR20210049026A (ko) 2021-05-04
EP3794355A1 (en) 2021-03-24
AU2019270404B2 (en) 2025-04-17
SG11202011369VA (en) 2020-12-30
AU2019270404A2 (en) 2020-12-17
IL278666B1 (en) 2025-02-01
US20210214793A1 (en) 2021-07-15
JP2021523744A (ja) 2021-09-09
AU2019270404A1 (en) 2020-12-10
MX2020012297A (es) 2021-03-25
JP2024075761A (ja) 2024-06-04
IL278666A (en) 2020-12-31
BR112020023259A2 (pt) 2021-02-23
US12247257B2 (en) 2025-03-11
JP7463351B2 (ja) 2024-04-08
CA3100171A1 (en) 2019-11-21
WO2019219831A1 (en) 2019-11-21
CN112424609A (zh) 2021-02-26

Similar Documents

Publication Publication Date Title
IL278666B2 (en) Blood biomarkers of stroke
Iba et al. Diagnosis of sepsis‐induced disseminated intravascular coagulation and coagulopathy
JP2021523744A5 (https=)
Chaturvedi et al. Diagnosis and management of the antiphospholipid syndrome
Bouman et al. Markers of coagulation, fibrinolysis and inflammation in relation to post‐thrombotic syndrome
Roldán et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
Lipinski et al. Early changes in serum creatinine level and estimated glomerular filtration rate predict pancreatic necrosis and mortality in acute pancreatitis: creatinine and eGFR in acute pancreatitis
Salvioni et al. Surfactant protein D (SP-D) as a biomarker of SARS-CoV-2 infection
NZ620799A (en) Molecular diagnostic test for cancer
Schutgens et al. The usefulness of five D-dimer assays in the exclusion of deep venous thrombosis
Yeager et al. Plasma proteomics of differential outcome to long‐term therapy in children with idiopathic pulmonary arterial hypertension
RU2016137685A (ru) Способ диагностики туберкулеза
Ji et al. Diagnostic and prognostic value of galectin‐3, serum creatinine, and cystatin C in chronic kidney diseases
BR112016019740A2 (pt) monitoramento do estado de inflamação
Katano et al. Anthropometric parameters-derived estimation of muscle mass predicts all-cause mortality in heart failure patients
JP2017505897A5 (https=)
Bonanad et al. Serum heat shock protein 60 in acute heart failure: a new biomarker?
Langsford et al. The association between biomarker profiles, etiology of chronic kidney disease, and mortality
Nosaka et al. Serum cystatin C as a biomarker of cardiac diastolic dysfunction in patients with cardiac disease and preserved ejection fraction
BR112018073214A2 (pt) métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador
Dur et al. Oxidative status and lymphocyte DNA damage in patients with acute pancreatitis and its relationship with severity of acute pancreatitis
BR112012024175A2 (pt) hbf e a1m como marcadores de estágio precoce para preeclampsia
WO2015197915A3 (en) Biochemical markers for use in determining risk of diabetes
BR112017015925A2 (pt) interceptador de erro (interceptador de erro ("error trap") de eletrodo de referência determinado a partir de um tempo de amostragem especificado e um tempo de amostragem predeterminado